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Assessment of potential anti-cancer stem cell
activity of marine algal compounds using an
in vitro mammosphere assay
Jo-Anne de la Mare1, Jason N Sterrenberg1, Mugdha G Sukhthankar1, Maynard T Chiwakata2, Denzil R Beukes2,
Gregory L Blatch1,3 and Adrienne L Edkins1*
Abstract
Background: The cancer stem cell (CSC) theory proposes that tumours arise from and are sustained by a
subpopulation of cells with both cancer and stem cell properties. One of the key hallmarks of CSCs is the ability to
grow anchorage-independently under serum-free culture conditions resulting in the formation of tumourspheres.
It has further been reported that these cells are resistant to traditional chemotherapeutic agents.
Methods: In this study, the tumoursphere assay was validated in MCF-7 cells and used to screen novel marine algal
compounds for potential anti-cancer stem cell (CSC) activity in vitro.
Results: MCF-7 breast cancer cells were observed to generate tumourspheres or mammospheres after 3-5 days
growth in anchorage-independent conditions and an apparent enrichment in potential CSCs was observed by an
increase in the proportion of CD44high/CD24low marker-bearing cells and Oct4 expression compared to those in the
bulk population grown in regular adherent conditions. Using this assay, a set of algal metabolites was screened for
the ability to inhibit mammosphere development as a measure of potential anti-CSC activity. We report that the
polyhalogenated monoterpene stereoisomers RU017 and RU018 isolated from the red alga Plocamium cornutum,
both of which displayed no cytotoxicity against either adherent MCF-7 breast cancer or MCF-12A non-transformed
breast epithelial cells, were able to prevent MCF-7 mammosphere formation in vitro. On the other hand, neither the
brown algal carotenoid fucoxanthin nor the chemotherapeutic paclitaxel, both of which were toxic to adherent
MCF-7 and MCF-12A cells, were able to inhibit mammosphere formation. In fact, pre-treatment with paclitaxel
appeared to enhance mammosphere formation and development, a finding which is consistent with the reported
resistance of CSCs to traditional chemotherapeutic agents.
Conclusion: Due to the proposed clinical significance of CSC in terms of tumour initiation and metastasis,
the identification of agents able to inhibit this subpopulation has clinical significance.
Keywords: Mammosphere assay, Cancer stem cells, Halogenated monoterpenes
Background
The cancer stem cell theory challenges the traditional
monoclonal models of cancer development and has
revolutionized the way we think about the origin and
progression of cancers [1,2]. This theory states that
tumours consist of a heterogenous population of cells
that is initiated and maintained by a subpopulation of
cells with both cancer and stem cell characteristics [2,3].
Most importantly the theory purports that cancer stem
cells (CSCs) are able to undergo assymetrical division,
meaning that they can both self-renew to produce more
cancer stem cells and differentiate to give rise to the
various cell types within a tumour [1,4].
The first solid tumour stem cells were identified
in breast cancer, where it was demonstrated that a
CD44+CD24- marker-bearing subpopulation could re-
generate a tumour from as little as 100 cells, whereas
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tens of thousands of cells from the bulk population
failed to do so [5]. Breast cancer stem cells (BCSCs)
have been isolated from both primary patient samples
and cell lines such as MCF-7 and SKBR3 [5-8]. These
CSCs can be isolated in a number of ways. Originally
BCSCs were identified and extracted from the bulk
population using fluorescence-activated cell sorting (FACS)
based on their specific cell surface markers, in this case
CD44+CD24-lin- [5,8]. Recently, breast cancer stem-like
cells have also been isolated based on their functional
characteristics; in particular their ability to grow anchorage-
independently in serum-free conditions [7,9]. In these
culture conditions non-stem cancer cells undergo anoikis,
a programmed cell death associated with loss of adhe-
sion, thus selecting for the CSC-like subpopulation
[10,11]. These CSC-like cells form tumourspheres or
mammospheres in suspension in vitro, have been
shown to be capable of in vivo tumour formation at
limiting cell dilutions and express high levels of stem
cell markers such as Oct4 [7,9,12].
While attention in the past decades has turned to-
wards marine natural products as a source of lead
anti-cancer compounds, marine algae have received
considerably less attention in terms of their potential
for bioactive metabolites than other marine organisms
such as sponges, Cnidarians and cyanobacteria [13]. In
addition, very few studies of the biological activity of
algal metabolites go beyond the standard in vitro cyto-
toxicity screening tests [14,15]. Recently, a number of
polyhalogenated monoterpene compounds were iso-
lated from the red algae Plocamium suhrii, Plocamium
cornutum and Plocamium corallorhiza collected from
the South African coastline, which were cytotoxic to
oesophageal and breast cancer cells in vitro [16,17].
We report that two polyhalogenated monoterpenes
isolated from Plocamium cornutum red algae inhibit
MCF-7 mammosphere formation in vitro, while having
no adverse effects on either the bulk MCF-7 popula-
tion or non-transformed MCF-12A breast epithelial
cells.
Results
Paclitaxel and fucoxanthin, but not the monoterpenes
RU017 and RU018, are toxic towards breast cancer and
non-transformed breast epithelial cells in vitro
The differential toxicity of the algal polyhalogenated
monoterpenes RU017 and RU018, as well as the carot-
enoid fucoxanthin (FXN) and the chemotherapeutic pac-
litaxel (Ptx), against breast cancer and non-transformed
breast epithelial cells was assessed by MTT assay. In this
assay, Ptx was found to decrease the percentage survival
of immortalized non-transformed breast epithelial cells
(MCF-12A) to approximately 70% at a concentration
equivalent to the IC50 value of the compound in both
metastatic (MDA-MB-231) and non-metastatic (MCF-7)
breast cancer cells in vitro (Table 1). In the case of FXN,
the metastatic MDA-MB-231 cells were more suscep-
tible to the carotenoid than non-metastatic MCF-7 cells,
while MCF-12A breast epithelial cells displayed a mod-
erate susceptibility to the compound at a concentration
of 10 μM. For the halogenated monoterpenes RU017
and RU018, neither of the compounds was toxic to
MCF-7 or MDA-MB-231 breast cancer or MCF-12A
non-transformed breast epithelial cell lines, even at a
concentration of 300 μM (Table 1).
MCF-7 breast cancer cells form mammospheres in
anchorage-independent serum-free culture conditions
The mammosphere assay was carried out for the MCF-7
breast cancer cell line in order to enrich for cancer stem
cell-like cells, which are able to grow in anchorage-
independent serum-free conditions [11]. The develop-
ment of non-adherent tumourspheres or mammospheres
[11] under these conditions was observed over the
course of one week. As depicted in Figure 1, the single-
cell suspension seeded on Day 0 had formed small, ir-
regular cell “clumps” by Day 1 (Figure 1Ai), which had
developed into small suspended colonies representative
of mammospheres by Day 3 (Figure 1Aii). By Day 5, the
mammospheres had increased in size to approximately
100 μM (0.1 mm) in diameter and displayed a more
regular spherical three-dimensional shape (Figure 1Aiii).
After seven days growth in anchorage-independent
conditions, the mammospheres, while remaining roughly
the same size as Day 5, began to exhibit different
morphologies (Figure 1Aiv). The most striking feature
of the Day 7 cultures was the formation of hollow
mammospheres; empty bubble-like structures surrounded
by one or more cells or small mammospheres attached to
what appeared to be an outer membrane of the hollow
spherical bodies (Figure 1Aiv, inset bottom right). The
number of mammospheres per well increased steadily
from Day 1 to Day 7 (Figure 1B), while the number of
single cells and clusters containing one to three cells
were observed to decrease with increased incubation
time (data not shown).
The enrichment of putative CSCs in mammospheres
assay was assessed by flow cytometry to detect
specific CSC markers, revealing that mammosphere-
derived cells (anchorage-independent) were enriched
for CD44high/CD24low CSC-like cells, displaying a
60.2% proportion of CD44high/CD24low fluorescent
events compared to 30.5% in the adherent bulk MCF-7
population (Figure 1C). The expression of CD44
cell surface marker in mammosphere-derived cells
was confirmed by confocal microscopy using fluo-
rescently tagged anti-CD44 antibodies (Figure 1D).
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Table 1 Differential cytotoxicity screening of paclitaxel and novel algal compounds against breast cancer and non-transformed breast epithelial cells
in vitro
Compound Structure MDA-MB-231 MCF-7 MCF-12A
IC50 value Concentration Percentage survival
Paclitaxel 112.82 ± 5.22 nM 94.97 ± 1.10 nM 100 nM 69.40 ± 2.8%
Fucoxanthin 11.07 ± 0.56 μM 23.00 ± 0.01 μM 10 μM 71.32 ± 9.2%
RU017 Non-toxic Non-toxic 300 μM 98.11 ± 4.6%
RU018 Non-toxic Non-toxic 300 μM 95.15 ± 3.4%
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Figure 1 breast cancer cells form cancer stem cell-enriched mammospheres under serum-free culture conditions. A) Alterations in
number, size and shape of mammospheres was observed over the course of seven days. Photographs were taken at Day 1 (i), Day 3 (ii), Day5 (iii)
and Day 7 (iv). Images are representative of at least three randomly selected fields. Insets show specific structural features of MCF-7
mammospheres at various stages of their development. Images were captured under a light microscope at 100× magnification using a Nikon
Coolpix 990 camera. Scale bars representative of 100 μm. Note: Insets not set to scale. B) Sphere forming efficiency SFE was calculated as the
number of mammospheres/spheres (average diameter = 100 μm) formed in 96 wells plated with a single cell divided by the original number of
single cells seeded and expressed as a percentage. Error bars represent the standard error of the mean where n = 3. C) Flow cytometry
histogram showing an increase in the CD44high/CD24low cell surface marker-bearing subpopulation between adherent and mammosphere-
derived (anchorage-independent) cells generated using FlowJo software (Tree Star Inc.). D) Confocal microscopic analysis of anchorage-
independent cells where Hoechst 33342 was used to stain nuclei (blue) while CD44 was stained with an allophycocyanin-conjugated antibody
(purple). Images were captured using a Zeiss LSM510 Meta confocal microscope. Scale bars represent 20 μm. E) Western analysis to assess Oct3/4
expression in mammospheres-derived cells compared to the bulk MCF-7 population. Western analyses were carried out on a total of 30 μg of
protein derived from whole cell lysates after cultivation in either regular adherent or serum-free anchorage-independent growth conditions. In
each case, lysates were probed for histone H3 as a loading control.
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Mammosphere-derived cells (anchorage-independent)
also displayed increased expression of the stem cell
marker Oct3/4 compared to those derived from the
bulk adherent population, as assessed by Western
analysis (Figure 1E).
The polyhalogenated monoterpene stereoisomers RU017
and RU018 inhibit the formation of MCF-7 mammospheres
The effect of the marine algal polyhalogenated mono-
terpenes RU017 and RU018, as well as the carotenoid
FXN, on the formation and development of MCF-7
mammospheres was assessed by addition of these com-
pounds to the culture medium either at seeding or
after four days growth in anchorage-independent
conditions (Figure 2). The compounds were added at a
concentration equivalent to the IC50 values in MDA-
MB-231 cells as determined by MTT assay (Table 1). In
the case of the non-toxic compounds RU017 and
RU018, a concentration of 300 μM was selected. This
high concentration of the compounds was not, how-
ever, toxic to the MCF-7 breast cancer or MCF-12A
breast epithelial cell lines under regular adherent con-
ditions (Table 1). However, under non-adherent condi-
tions, both of the latter compounds prevented the
formation of MCF-7 mammospheres, leaving only sin-
gle cells or clusters of two or three cells in the treated
samples by Day 3, which were further decreased by
Day 6 (Figures 2Ab and 2Ac). In comparison, MCF-7
cells treated with the vehicle control (dimethyl
sulphoxide, DMSO) formed distinct mammospheres by
Day 3 (Figure 2Aa ii). The carotenoid FXN caused a
statistically significant decrease in the sphere forming
efficiency (SFE) both at Day 3 and Day 6 (Figure 2B)
and resulted in smaller mammospheres in general
compared to the control (Figure 2Ad vs. Figure 2Aa). The
compound was, however, unable to inhibit mammosphere
formation completely (Figures 2Ad and 2B).
For all of the algal compounds tested, the effect of the
compounds on sphere forming efficiency when added at
Day 4 differed from that obtained when the compounds
were added upon seeding of the MCF-7 cells (Figure 2A iii
vs. iv). When added to existing MCF-7 mammospheres on
Day 4, none of the compounds screened were able to re-
move the existing MCF-7 mammospheres or prevent their
further development (Figures 2A iv and 2B). The addition
of FXN after four days resulted in the formation of much
larger, irregularly shaped mammospheres than those ob-
served in the DMSO-treated MCF-7 cells (Figure 2Ad iv vs.
Figure 2Aa iv). In contrast to the effects when added upon
seeding, neither of the stereoisomers RU017 or RU018 were
able to eliminate the MCF-7 mammospheres or affect their
further development when added at Day 4 (Figures 2Ab iv
and 2Ac iv, respectively).
The WST-1 cell proliferation assay was carried out on
treated mammospheres (treated both at seeding and
on Day 4) after eight days growth in anchorage-
independent culture conditions. The percentage survival
values for each sample were calculated relative to the
DMSO-treated vehicle control (taken as 100%) after 8
days growth in anchorage-independent conditions when
equal numbers of cells are seeded, and are indicated in
Figure 2C. While FXN produced a (non-significant) re-
duction in cellular survival to 70% when added upon
seeding, the compound was unable to decrease cell
survival when added four days after seeding (107% sur-
vival relative to DMSO-treated cells). The halogenated
monoterpenes RU017 and RU018 both resulted in statis-
tically significant decreases in cellular survival (53% and
44%, respectively) when added at Day 0, while the slight
reduction in survival (to 84% and 77%, respectively),
when added at Day 4 was not statistically significant.
In order to further characterize the effect of RU017
and RU018 on sphere forming efficiency as observed in
Figure 2B, untreated mammospheres were dissociated
and seeded into regular anchorage-dependent growth
conditions, followed by treatment with either of the algal
compounds and assessed for viability using an MTT
assay. In this assay, it was found that the algal com-
pounds had a small but statistically significant effect on
cell viability when compared to the vehicle control, but
that neither were able to reduce cell viability to below
78% (Figure 2D). This minor reduction in viability was
similar to that observed when cells were treated with the
monoterpenes in anchorage-independent mammosphere
conditions after four days growth, but differed from that
observed when cells were treated upon seeding into
anchorage-independent culture conditions (Figure 2C).
The inhibitory effect of the marine algal compounds
RU017 and RU018 on MCF-7 mammosphere formation
in vitro is dose-dependent
The effects of the algal compounds RU017, RU018 and
FXN on the formation and development of MCF-7
mammospheres were more thoroughly investigated by
determining whether the observed alterations to the
mammospheres were dose-dependent. In addition, the
effect of various concentrations of the chemotherapeutic
agent, Ptx, on sphere forming efficiency was assessed.
For both of the monoterpene stereoisomers, RU017 and
RU018, the inhibition of MCF-7 mammosphere forma-
tion appeared to be dose-dependent (Figures 3A i and ii,
respectively; Figure 3B). In each case, treatment with 50
μM, but not 25 μM, of the compounds had a significant
effect on the number (Figure 3B) and size of the MCF-7
mammospheres formed after six days, although the
mammospheres treated with 25 μM were observed to be
more irregular in shape when compared to the DMSO-
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treated control (Figures 3Ab and 3Ac, i and ii respect-
ively). The latter concentrations of RU017 and RU018
did not, however, reduce cellular viability of the treated
mammospheres compared to the DMSO control as de-
termined by WST-1 assay (Figure 3C). For both haloge-
nated monoterpenes, treatment with 100 μM appeared
to inhibit mammosphere formation, resulting only in
small cell clumps (Figure 3Ad, i and ii, respectively).
However, in the WST-1 assay, the decrease in percent-
age viability relative to the control was statistically
significant only in the case of RUMB-018 (Figure 3C).
Treatment of MCF-7 cells upon seeding in anchorage-
independent conditions with 300 μM of either RU017 or
RU018 prevented mammosphere formation entirely and
significantly reduced cell viability for both compounds
(Figures 3Ae i and ii, respectively; Figures 3B and C).
In the case of the carotenoid compound FXN, none of
the concentrations tested were able to completely elim-
inate mammosphere formation when added to MCF-7
cells upon seeding into anchorage-independent conditions,
although a dose-dependent decrease in mammosphere size
was observed (Figure 3A iii). The effects of FXN on sphere
forming efficiency and cell viability, however, were not
dose-dependent (Figures 3B and C). For all concentrations
tested, FXN was unable to reduce cell viability to below
76% relative to the DMSO-treated control (Figure 3C).
The chemotherapeutic drug Ptx appeared to increase
the number of MCF-7 mammospheres when 50 nM was
added upon seeding (Figures 3Ab iv and 3B), while treat-
ment with 100 nM had little effect on sphere forming
efficiency compared to the DMSO-treated control
(Figures 3Ac iv and 3B). This was despite the latter con-
centration being reported as the IC50 value for MCF-7
cells under adherent conditions [18]. In comparison,
using the WST-1 cytotoxicity assay, Ptx led to a minor
but statistically significant reduction in mammosphere
viability when added at both 50 and 100 nM in
anchorage-independent mammosphere conditions. Im-
portantly, neither of the concentrations tested were able
to reduce cellular viability to below 84% (Figure 3C).
Pre-treatment of adherent MCF-7 cultures with algal
compounds or Ptx does not prevent mammosphere
formation
The compounds RU017, RU018, FXN and Ptx were used
to pre-treat MCF-7 cells grown under normal anchorage-
dependent conditions prior to seeding under anchorage-
independent mammosphere conditions. The consequences
of such treatment on mammosphere development and via-
bility were compared to those obtained for treatment of
mammospheres at seeding (Day 0) or after four days
growth in mammosphere conditions (Day 4).
For all four of the compounds RU017, RU018, FXN
and Ptx, pre-treatment of MCF-7 cells in anchorage-
dependent culture conditions prior to seeding into
anchorage-independent conditions in the mammosphere
assay was unable to either prevent mammosphere
formation (Figure 4A i) or effectively reduce cell viability
relative to the DMSO control (Figure 4C). Although
pre-treatment with FXN resulted in a statistically signifi-
cant decrease in sphere forming efficiency after 6
days incubation in anchorage-independent conditions
(Figure 4B), the compound did not completely inhibit
mammosphere formation (Figure 4Ai d) or reduce cellu-
lar viability of pre-treated mammospheres (Figure 4C).
Interestingly, pre-treatment with the chemotherapeutic
agent Ptx, though having little effect on sphere forming
efficiency (Figure 4B), appeared to produce larger, more
regular shaped mammospheres when compared to the
DMSO vehicle-treated control (Figure 4Ai e vs. a), while
having little effect on cell viability (Figure 4C).
Treatment of second and third generation MCF-7
mammospheres with the algal compounds RU017 and
RU018 causes a dose-dependent decrease in sphere
forming efficiency
The inhibitory effect on MCF-7 mammosphere formation
by the halogenated monoterpenes RU017 and RU018 was
further assessed by screening these compounds against
second and third generation mammospheres. Untreated
mammospheres were dissociated, reseeded under
anchorage-independent conditions and treated with
either 100 μM or 300 μM of RU017 or RU018. In both
cases, although the compounds were unable to com-
pletely prevent MCF-7 mammosphere formation as was
the case for primary mammospheres, treatment upon
seeding of second and third generation mammospheres
resulted in a dose-dependent decrease in sphere forming
efficiency (Figure 5A and B). However, the decrease in SFE
was greater for both compounds in the second vs. the
third generation mammospheres. The inhibitory effect
on mammosphere formation was not equal between
the stereoisomers, with RU018 being more effective
than RU017 in inhibiting both second and third gener-
ation mammosphere formation (Figure 5A and B).
However, neither of the compounds had a significant
effect on cell viability in either second or third gener-
ation mammosphere assays (data not shown).
Discussion
In this study, the tumoursphere or mammosphere sys-
tem was used to allow for the screening of marine algal
compounds for potential anti-cancer stem cell (CSC)
activity. The relatively small number of mammospheres
formed compared to the total of 1000 cells seeded,
as well as the enrichment in Oct4 expression and
CD44high/CD24low marker-bearing cells in isolated
mammospheres, lent credence to the hypothesis that
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Figure 2 The polyhalogenated monoterpenes RU017 and RU018 inhibit the formation but not development of MCF-7 mammospheres.
A) Mammosphere cultures were treated with either the DMSO vehicle control (a), 300 μM of either of the halogenated monoterpene
stereoisomers RU017 (b) or RU018 (c) or10 μM fucoxanthin (FXN) (d). The latter concentrations were derived from the IC50 values in MDA-MB-231
or MCF7 breast cancer and MCF12A non-cancerous cells grown in anchorage-dependent conditions in the case of FXN. Images were captured
under a light microscope at either 400× or 100× magnification using a Nikon Coolpix 990 camera on Day 1 (i), Day 3 (ii) and Day 6 (ii) after
treatment with the relevant compounds upon seeding and on Day 6 for mammospheres treated with compounds four days after seeding (iv).
Images were representative of at least three randomly selected fields for each treatment. Analysis of images and calculation of scale was carried
out using ImageJ (NIH freeware). Scale bars representative of 0.1 mm. B) Sphere forming efficiency (SFE) and C) mammosphere viability on Day 8
as determined by WST-1 assay. D) Untreated mammospheres were dissociated and seeded as a single cell suspension into regular culture media
containing either the vehicle control or 300 μM of RU017 or RU018, cultured under adherent conditions and assessed for viability by means of an
MTT assay. The percentage viability in C) and D) was calculated relative to the DMSO vehicle-treated control (taken as 100%) when an equal
numbers of cells are seeded and treated for the same period. For B), C) and D) error bars indicate the standard error of the mean where n = 3
(B) or 5 (C and D). Statistical significance was calculated using a Students t-test (**p < 0.01, *p < 0.05).
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only a specific subset of the bulk MCF-7 population,
displaying unique functional and phenotypic character-
istics, was capable of propagation in suspension and
validated the mammosphere assay employed [7,19].
While the addition of the test compounds at the stage
of seeding of MCF-7 cells into anchorage-independent
culture conditions assessed the effect on mammosphere
formation, dosing with the compounds to existing
mammospheres on Day 4 measured the ability to remove
the mammospheres or alter further development. In
addition, pre-treatment with compounds prior to seeding
into mammosphere conditions provided preliminary insight
Figure 3 (See legend on next page).
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as to the mechanism of action, in particular the ability to
remove CSCs from the bulk population when grown under
adherent conditions.
The commonly used chemotherapeutic agent, Ptx, was
unable to prevent mammosphere formation when added
at a concentration which was toxic to both breast cancer
and non-transformed breast epithelial cells under adher-
ent conditions, nor was the drug able to reduce
mammosphere viability to below 84%. This is consistent
with previous reports which demonstrated that 10 ng/L
(12 pM) of Ptx had no effect on MDA-MB-231
mammosphere survival [20]. In addition, when added at
a concentration of roughly half the IC50 value of MCF-7
cells, Ptx appeared to promote mammosphere formation
and pre-treatment of MCF-7 cells prior to seeding pro-
duced larger, more defined mammospheres. This data
suggests that traditional chemotherapy regimens such as
Ptx may be ineffective against cancer cells growing in
suspension (as occurs in the bloodstream during metas-
tasis) or that the cancer stem cell sub-population may be
resistant to these agents, as has been suggested in the
literature [21]. However, significant further work is
required in order to substantiate these hypotheses.
The carotenoid compound, fucoxanthin (FXN), was
shown to be toxic to MDA-MB-231 and MCF-7 breast
cancer cells and, to a lesser extent, non-cancerous
MCF12A breast epithelial cells. However, the com-
pound was unable to prevent the formation of MCF-7
mammospheres when added either upon seeding or at
Day 4, or when used to pre-treat MCF-7 cells prior to
seeding into anchorage-independent mammosphere condi-
tions. The inability of FXN to inhibit mammosphere forma-
tion and development revealed that the anti-mammosphere
activity was not a feature shared by all compounds of
marine algal origin.
In the case of the halogenated monoterpene stereoiso-
mers RU017 and RU018, both of which were shown to
have no effect on the survival and proliferation of either
breast cancer cells or non-transformed breast epithelial
cells in vitro, the compounds were able to completely
inhibit mammosphere formation when added to MCF-7
cells upon seeding in the mammosphere assay. Since
mammosphere formation is reportedly dependent on the
presence of CSC [9] and isolated mammospheres in this
study showed an increase in cells expressing the CD44
+/CD24- breast cancer stem cell (BCSC) phenotype, the
ability of RU017 and RU018 to inhibit mammosphere
formation suggested that these compounds have putative
anti-CSC activity and may inhibit a signal transduction
pathway which is essential in mammosphere formation.
Compounds RU017 and RU018 were not, however, able
to remove existing mammospheres when added on Day
4. This could be attributed either to the inability of the
compounds to penetrate the mammospheres or could
indicate that they were only inhibitory during the early
stages of mammosphere formation. This was supported
by the fact that pre-treatment of MCF-7 cells with either
RU017 or RU018 prior to seeding into anchorage-
independent conditions had no effect on the ability of
the cells to form mammospheres under these conditions.
A possible explanation for this is that the effect of the
compounds on the MCF-7 cells may be specific to their
initial propagation under anchorage-independent serum-
free growth conditions. This is supported by the fact that
dissociated untreated mammospheres seeded into regu-
lar anchorage-dependent conditions and then treated
with the algal compounds experience only a minor
decrease in viability as opposed to the large decrease in
viability seen when cells are treated with these compounds
upon seeding into anchorage-independent conditions.
To further assess the efficacy of the algal compounds,
RU017 and RU018, their effect on sphere forming effi-
ciency was assessed for second and third generation
mammospheres. In both cases, although the compounds
were unable to prevent second or third generation
mammosphere formation as was the case for primary
mammospheres, they did result in a dose-dependent
decrease in sphere forming efficiency. This reduced
ability of the algal compounds to inhibit mammosphere
formation in subsequent generations may be due to
(See figure on previous page).
Figure 3 The inhibitory effect of RU017 and RU018 on MCF-7 mammosphere formation is dose-dependent. A) Photographs of
mammospheres formed after six days incubation in anchorage-independent serum-free conditions. MCF-7 cells were seeded as a single cell
suspension into media containing either (a) DMSO vehicle control or a range of concentrations of the halogenated monoterpene stereoisomers
(i) RU017 or (ii) RU018 [(b)25, (c)50, (d)100 or (e)300 μM], (iii) fucoxanthin [(b)5, (c)10 or (d)15 μM] or (iv) paclitaxel [(b)50 or (c)100 nM]. The latter
concentrations of compounds tested was informed by the cytotoxicity values observed under adherent conditions. Cells were photographed
under a light microscope at 100× magnification. All images are representative of at least three randomly selected fields and were set to the same
scale using ImageJ (NIH freeware). Scale bars representative of 0.1 mm. B) Quantification of the mammospheres generated in terms of sphere
forming efficiency (SFE) after six days for the various treatments. SFE was calculated as the number of spheres (average diameter = 100 μm)
formed in 96 wells plated with a single cell divided by the original number of single cells seeded and expressed as a percentage. C) Cell viability
in treated mammosphere samples as assessed by WST-1 assay. The percentage viability after each of the treatments in C) was calculated relative
to the DMSO-treated negative control (taken as 100%) after 8 days growth when an equal numbers of cells are seeded. Error bars indicate
standard deviation where n = 3 (B) or 5 (C). Statistical significance of the differences in SFE and percentage survival relative to the DMSO control
were calculated using a Students t-test (**p < 0.01, *p < 0.05).
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Figure 4 Pre-treatment of MCF-7 cells with RU017/RU018 under adherent conditions is unable to prevent mammosphere formation.
A) Treatment of MCF-7 cells was with a) DMSO vehicle control or either of the halogenated monoterpene stereoisomers b) RU017 or c) RU018
(100 μM), d) fucoxanthin (10 μM) or e) paclitaxel (100 nM). For pre-treatment, MCF-7 cells were cultured in regular anchorage-dependent culture
conditions containing the compound of interest, before trypsinizing and transferring to anchorage-independent serum-free mammosphere
conditions as a single cell suspension. The Day 0 and Day 4 samples refer to treatment of MCF-7 cells either upon seeding or after 4 days
growth, respectively, in anchorage-independent serum-free culture conditions. Images were captured under a light microscope at 100×
magnification. Each image is representative of at least 3 randomly selected fields. Images were set to the same scale using ImageJ (NIH freeware).
Scale bars are equivalent to 0.1 mm. B) Quantification of mammospheres formed in terms of sphere forming efficiency (SFE) after six days for
each treatment. SFE was calculated as the number of spheres (average diameter = 100 μm) formed in 96 wells plated with a single cell divided
by the original number of single cells seeded and expressed as a percentage. C) Assessment of cell viability in treated mammospheres by WST-1
assay. The percentage viability after each of the treatments in C) was calculated relative to the DMSO-treated negative control (taken as 100%)
after 8 days growth when an equal numbers of cells are seeded. In both B) and C), error bars indicate the standard error of the mean where
n = 3 (B) or 5 (C). Statistical significance of the differences in SFE and percentage survival relative to the DMSO control were calculated using a
Students t-test (**p < 0.01, *p < 0.05).
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accumulated changes in growth characteristics of the
cells as a consequence of prolonged culturing under
anchorage-independent serum-free conditions, resulting
in a more aggressive phenotype. This could also account
for the increase in sphere forming efficiency in the ve-
hicle control for the third generation as compared to
that of the second generation. Interestingly, RU018
appeared more effective than RU017 in inhibiting second
and third generation mammosphere formation, a finding
which was consistent with the trend observed in terms
of first generation mammosphere cell viability. This data
implies that the stereochemistry of the monoterpene
compounds plays a role in their mechanism of action
against MCF-7 mammospheres.
The identification of CSCs within breast tumours has
resulted in a major shift in focus in terms of the devel-
opment of novel therapies to treat this disease [22]. It
is now thought that complete eradication and preven-
tion of relapse requires the removal of the stem cell
subpopulation within a tumour [23]. Traditional treat-
ments, such as chemotherapy and radiation, were ori-
ginally developed to kill the rapidly dividing bulk
population of cells within the tumour [22]. However,
while these therapies are able to shrink the tumour, the
effects are often transient and recurrence remains a
reality for a substantial proportion of sufferers [22,24].
This has been attributed to the resistance of the CSC
subpopulation to traditional therapies, such that these
highly tumourigenic cells remain behind after chemo-
therapy or radiation treatment [23,24]. Therefore,
there is a need to find agents which are able to specific-
ally inhibit CSCs.
Conclusions
The body of work described herein reports the first
screening of marine algal compounds in a mammosphere
assay. In particular, screening of the compounds FXN,
RU017 and RU018 revealed that the latter monoterpene
stereoisomers inhibited MCF-7 mammosphere formation.
In contrast, the commonly used chemotherapeutic drug
Ptx appeared to enhance both the formation and matur-
ation of early mammospheres. More work is required to
determine the specific molecular mechanisms mediating
the mammosphere inhibitory activity of the halogenated
monoterpenes as well as their respective cellular targets.
In addition, the concentration of RU017 and RU018 re-
quired for such activity falls outside the druggable range
and rational chemical modification is needed to improve
their efficacy. Since the compounds form part of a struc-
tural series isolated from Plocamium corallorhiza and
Plocamium cornutum [17], they could find application as
tool compounds to study CSC selectivity in halogenated
monoterpenes.
Figure 5 The halogenated monoterpenes RU017 and RU018
have a dose-dependent inhibitory effect on second and third
generation mammosphere formation. Untreated mammospheres
of first and second generation were dissociated and reseeded into
anchorage-independent conditions in serum-free culture media
containing the compounds of interest in order to assess second (A) and
third generation (B) sphere forming efficiency (SFE), respectively. In both
cases, mammosphere-derived MCF-7 cells were seeded as a single cell
suspension into media containing either the DMSO vehicle control or
either 100 or 300 μM of the halogenated monoterpene stereoisomers
RU017 or RU018. SFE was calculated as the number of spheres (average
diameter = 100 μm) formed after six days in 96 wells plated with a
single cell divided by the original number of single cells seeded and
expressed as a percentage. Error bars indicate the standard error of the
mean where n = 5. Statistical significance of the differences in SFE
relative to the DMSO control were calculated using a Students t-test
(**p < 0.01, *p < 0.05).
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Methods
Reagents
Dulbecco’s Modified Eagle Medium (DMEM) containing
Glutamax™, Ham’s F-10 Medium containing Glutamax™,
foetal calf serum (FCS), B-27 supplement and penicillin-
streptomycin-amphotericin (PSA) were obtained from
Gibco (Invitrogen). Epidermal growth factor (EGF), basic
fibroblast growth factor (bFGF), hydrocortisone, heparin,
Accutase®, paclitaxel and fucoxanthin were from Sigma-
Aldrich. Insulin was obtained from NovoRapid (Novo
Nordisk Pharmaceuticals). The MTT and WST-1 Cell
Proliferation kits were from Roche. Hoescht 33342
dye for flow cytometric analyses was obtained from
Invitrogen, while the allophycocyanin (APC)-conjugated
mouse anti-human CD24 and fluorescein isothiocyanate
(FITC)-conjugated rat anti-human CD44 antibodies
were from e-Biosciences, as were the isotype controls.
The mouse anti-human Oct3/4 antibody was obtained
from Santa Cruz, while the goat anti-mouse and goat anti-
rabbit antibodies were from Sigma. The rabbit anti-histone
H3 antibody was from Cell Signalling Technologies.
Cell lines and culture conditions
The metastatic breast cancer cell line, MDA-MB-231
(ATCC: HTB-26) was maintained in culture in Dulbecco’s
Modified Eagle Medium (DMEM) containing Glutamax™
and supplemented with 5% (v/v) heat-inactivated FCS, 100
U/ml penicillin, 100 μg/ml streptomycin and amphotericin
(PSA) at 37ºC in a humidified 9% CO2 incubator. The im-
mortalized, non-transformed breast epithelial MCF-12A
cells (ATCC: CRL-10782) were maintained using a 1:1 ratio
of Ham’s F10 and DMEM containing Glutamax™ and
supplemented with 10% (v/v) heat-inactivated FCS, PSA (as
for MDA-MB-231 cells), 20 ng/ml EGF, 500 ng/ml hydro-
cortisone and 10 μg/ml insulin. The breast cancer cell line
MCF-7 (ATCC: HTB-22) was maintained in culture either
in anchorage-dependent or anchorage-independent condi-
tions. In the former, cells were cultured as for the MDA-
MB-231 line in regular 96-well plates.
Mammosphere assay
Anchorage-independent growth was assessed by
mammosphere assay, modified from that previously
described [11]. Briefly, cells were lifted with 0.25%
(v/v) trypsin in 0.61% (w/v) ethylenediaminetetracetic
acid (EDTA), washed with phosphate-buffered saline
(PBS) (137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4,
2 mM KH2PO4 pH 7.4) and passed through a 40 μM
cell strainer (BD Biosciences) to achieve a single cell
suspension. Cell were seeded at a density of 1000
cells per well in ultralow attachment 96-well plates
containing DMEM with Glutamax™ supplemented with
1% (v/v) PSA, 2% (v/v) B-27 supplement, 20 ng/ml
EGF and bFGF, 4 ng/ml heparin and 10 μg/ml insulin.
Treatment with either 0.61% (v/v) dimethyl sulphoxide
(DMSO) vehicle control or paclitaxel (Sigma-Aldrich),
fucoxanthin (Sigma-Aldrich), RU017 or RU018 was
carried out either upon seeding or at Day 4 for quintu-
plicate samples. The cells were fed every 48 hours by
the addition of fresh medium to existing culture vol-
ume and the resultant mammospheres photographed
in triplicate using a Nikon camera (Coolpix 990) attached
to a light microscope at 100 × magnification. Images were
analyzed and scale bars calculated using ImageJ (NIH).
Quantification in terms of Sphere Forming Efficiency
(SFE) was carried out by counting of mammospheres
under a light microscope at 10× magnification and
reported as the number of mammospheres/spheres
(average diameter = 100 μm) formed in 96 wells divided
by the original number of single cells seeded and
expressed as a percentage. Statistical significance for the
various treatments was assessed using a Student’s t-test
in GraphPad Prism (GraphPad Inc.).
Dissociation of mammospheres for cell viability as-
says and screening of second and third generation
mammospheres was achieved using Accutase® solution
(Sigma). Briefly, the mammospheres were collected by
centrifugation, resuspended in 200 uL of 1 × Accutase®
solution and incubated for 15 minutes before passing
through a 40 μM cell strainer (BD Biosciences) to
achieve a single cell suspension. Mammosphere-
derived cells were seeded at a density of 6000 cells per well
under regular anchorage-dependent conditions for cell
viability analysis by MTT assay and at 1000 cells per well
under anchorage-independent mammosphere culture con-
ditions for second and third generation screening assays.
Cell surface marker analysis by flow cytometry
Adherent MCF-7 cells were lifted using 0.25% (v/v) trypsin
and washed with PBS, while anchorage-independent cells
were collected by centrifugation (800 × g, 2 minutes),
washed with PBS and dissociated using 0.25% (v/v) trypsin.
In both cases, cells were resuspended to a final concentra-
tion of 5 × 106 cells/ml in PBS and 5 × 105 cells (100 μl)
incubated with 0.5 – 1 μg of fluorophore-conjugated anti-
CD44 and anti-CD24 antibodies or isotype matched control
antibodies at 4 °C for 60 minutes. Unstained samples
containing no antibodies were also included. The cells were
washed twice with ice-cold PBS and collected by centrifu-
gation as previously described, before analysis using a FACS
Aria III flow cytometer. The fluorescein isothiocyanate
(FITC) was excited at 488 nm and emission recorded in the
530/30 filter channel, while the 633 nm laser was used
to excite the APC (allophycocyanin) fluorophore with
emission recorded in the 660/20 filter channel (APC).
Compensation values for FITC and APC fluorescence over-
lap were established using compensation controls and cop-
ied to all subsequent analyses. A total of 30 000 events
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were recorded for each sample. Flow cytometry data was
analysed using FlowJo software (Tree Star Inc.). Isotype
controls were used to establish fluorescence threshold gates
with the gates set on the isotype control to exclude the
major population of cells. Gates were then copied onto the
respective samples in order to determine the CD44/CD24
expression profile of the sample. Two-colour dot plots were
then constructed showing FITC (CD24) fluorescence on
the y-axis and APC (CD44) fluorescence on the x-axis.
Confocal microscopy analysis of anchorage-independent
MCF-7 breast cancer cells
Anchorage-independent cells were seeded into 8-well
chambered coverslips overnight. Cells were fixed by flash
incubation in ice-cold methanol and left to air-dry before
incubation in a blocking solution [1% (w/v) bovine serum
albumin (BSA) in Tris-buffered saline (TBS)] at room
temperature for 30 minutes. A primary antibody solution
containing anti-CD44 conjugated to APC in 0.1% (w/v)
BSA/TBS was added to the cells and incubated overnight at
4ºC. Cells were washed twice with agitation in blocking
solution, after which the cells were washed in distilled water
containing 1 μg/ml of DNA binding dye Hoechst 33342.
The coverslips were mounted onto glass slides using Dako
mounting media (Dako). Differential contrast (DIC) and
fluorescent images were taken using a Zeiss LSM510 meta
confocal microscope.
Western blot analysis
MCF-7 cells were seeded at a density of 4000 cells per
well in anchorage independent mammosphere conditions
and mammospheres allowed to develop over 8 days.
In addition MCF-7 cells were cultured in anchorage-
dependent regular culture conditions and lifted using 0.25%
(v/v) trypsin. Whole cell lysates were prepared from adher-
ent and mammosphere cultures. Briefly, cells were collected
by centrifugation at 2000 rpm for 3 minutes and
resuspended in 100 μM SDS sample buffer (125 mM Tris–
HCl pH 6.8, 2% (w/v) SDS, 20% (v/v) glycerol, 0.2% (w/v)
bromophenol blue) before boiling for 5 minutes. Thereafter,
30 ug of protein from each lysate was loaded onto a 12%
SDS polyacrylamide gels, separated by electrophoresis and
transferred onto a nitrocellulose membrane, before probing
with mouse anti-Oct3/4 (1 in 2000) at 4ºC overnight. The
HRP-conjugated anti-mouse secondary antibody was
detected using the ECL Advanced Western Blotting Kit
(GE Healthcare) and visualized using the Molecular Imager
ChemiDoc XRS System (BioRad). Lysates were probed with
rabbit anti-histone H3 antibody (1 in 2500) as a loading
control.
Extraction of compounds from marine algae
Specimens of the red alga Plocamium cornutum were
gathered off the south-east coast of South Africa and
the halogenated monoterpenes extracted as previously
described [25].
Cell viability assays
Cell viability after treatment with the compounds was eval-
uated by means of the MTT assay in the case of adherent
cells and WST-1 assay in the case of mammospheres,
according to manufacturer’s instructions. For both assays,
percentage viability after treatment with compounds was
calculated relative to the DMSO vehicle control (taken as
100% viability) when equal numbers of cells are seeded. For
the MTT Cell Proliferation Kit 1, MDA-MB-231, MCF-7
or MCF-12A cells were seeded at a density of 6000 cells/
well in 96-well plates and assessed for viability as previously
described [17]. In the case of the WST-1 kit, after treatment
and growth of the mammospheres for 8 days, 10 μL of a 5
mg/ml WST-1 reagent was added to each well and incu-
bated for a further 4 hours before reading the absorbance
at 450 nm. Viability assays were carried out in quintuplicate
and statistical significance assessed using GraphPad Prism.
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